Literature DB >> 14615464

CNS and cutaneous involvement in patients with chronic myeloid leukemia treated with imatinib in hematologic complete remission: two case reports.

E Abruzzese, M Cantonetti, L Morino, G Orlandi, A Tendas, M I Del Principe, M Masi, S Amadori, A Orlandi, L Anemona, Elena Campione.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14615464     DOI： 10.1200/JCO.2003.99.170

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

Review 1.  Targeting PI3K/AKT/mTOR network for treatment of leukemia.

Authors:  Jessika Bertacchini; Nazanin Heidari; Laura Mediani; Silvano Capitani; Mohammad Shahjahani; Ahmad Ahmadzadeh; Najmaldin Saki
Journal:  Cell Mol Life Sci       Date:  2015-02-25       Impact factor: 9.261

2.  Cerebral relapse of metastatic gastrointestinal stromal tumor during treatment with imatinib mesylate: case report.

Authors:  Brett Hughes; Desmond Yip; David Goldstein; Paul Waring; Victoria Beshay; Guan Chong
Journal:  BMC Cancer       Date:  2004-10-09       Impact factor: 4.430

3.  Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platform.

Authors:  Peter Valent; Thomas Lion; Dominik Wolf; Christian Sillaber; Hermine Agis; Andreas Petzer; Alois Lang; Peter Kalhs; Dietmar Geissler; Richard Greil; Werner Linkesch; Sonja Burgstaller; Josef Thaler; Günther Gastl
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

4.  Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches.

Authors:  Peter Valent
Journal:  Biologics       Date:  2007-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.